Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 5.1% – Should You Sell?

Ernexa Therapeutics Inc. (NASDAQ:ERNA) shares fell 5.1% on Monday . The stock traded as low as $1.25 and last traded at $1.29. 32,715 shares changed hands during trading, a decline of 27% from the average session volume of 44,702 shares. The stock had previously closed at $1.36.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Ernexa Therapeutics Price Performance

The company has a market cap of $9.73 million, a P/E ratio of -0.41 and a beta of 6.20. The stock has a fifty day moving average price of $1.40 and a two-hundred day moving average price of $1.63.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings results on Friday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.